325 related articles for article (PubMed ID: 17454265)
41. NKT cells: In the beginning..
Macdonald HR
Eur J Immunol; 2007 Nov; 37 Suppl 1():S111-5. PubMed ID: 17972354
[TBL] [Abstract][Full Text] [Related]
42. iNKT cells in microbial immunity: recognition of microbial glycolipids.
Kinjo Y; Ueno K
Microbiol Immunol; 2011 Jul; 55(7):472-82. PubMed ID: 21434991
[TBL] [Abstract][Full Text] [Related]
43. Novel synthesis of alpha-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity.
Lee A; Farrand KJ; Dickgreber N; Hayman CM; Jürs S; Hermans IF; Painter GF
Carbohydr Res; 2006 Dec; 341(17):2785-98. PubMed ID: 17014832
[TBL] [Abstract][Full Text] [Related]
44. A closer look at CD1d molecules: new horizons in studying NKT cells.
Stronge VS; Salio M; Jones EY; Cerundolo V
Trends Immunol; 2007 Oct; 28(10):455-62. PubMed ID: 17825624
[TBL] [Abstract][Full Text] [Related]
45. Characterization and functional analysis of mouse invariant natural T (iNKT) cells.
Bezbradica JS; Stanic AK; Joyce S
Curr Protoc Immunol; 2006 Jul; Chapter 14():14.13.1-14.13.27. PubMed ID: 18432968
[TBL] [Abstract][Full Text] [Related]
46. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice.
Forestier C; Molano A; Im JS; Dutronc Y; Diamond B; Davidson A; Illarionov PA; Besra GS; Porcelli SA
J Immunol; 2005 Jul; 175(2):763-70. PubMed ID: 16002672
[TBL] [Abstract][Full Text] [Related]
47. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.
Silk JD; Salio M; Reddy BG; Shepherd D; Gileadi U; Brown J; Masri SH; Polzella P; Ritter G; Besra GS; Jones EY; Schmidt RR; Cerundolo V
J Immunol; 2008 May; 180(10):6452-6. PubMed ID: 18453560
[TBL] [Abstract][Full Text] [Related]
48. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.
Van Kaer L; Parekh VV; Wu L
Immunotherapy; 2011 Jan; 3(1):59-75. PubMed ID: 21174558
[TBL] [Abstract][Full Text] [Related]
49. CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity.
Nieuwenhuis EE; Gillessen S; Scheper RJ; Exley MA; Taniguchi M; Balk SP; Strominger JL; Dranoff G; Blumberg RS; Wilson SB
Exp Dermatol; 2005 Apr; 14(4):250-8. PubMed ID: 15810882
[TBL] [Abstract][Full Text] [Related]
50. A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells.
Liu Y; Goff RD; Zhou D; Mattner J; Sullivan BA; Khurana A; Cantu C; Ravkov EV; Ibegbu CC; Altman JD; Teyton L; Bendelac A; Savage PB
J Immunol Methods; 2006 May; 312(1-2):34-9. PubMed ID: 16647712
[TBL] [Abstract][Full Text] [Related]
51. iNKT-cell responses to glycolipids.
Parekh VV; Wilson MT; Van Kaer L
Crit Rev Immunol; 2005; 25(3):183-213. PubMed ID: 16048435
[TBL] [Abstract][Full Text] [Related]
52. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
53. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells.
Uemura Y; Liu TY; Narita Y; Suzuki M; Nakatsuka R; Araki T; Matsumoto M; Iwai LK; Hirosawa N; Matsuoka Y; Murakami M; Kimura T; Hase M; Kohno H; Sasaki Y; Ichihara Y; Ishihara O; Kikuchi H; Sakamoto Y; Jiao SC; Senju S; Sonoda Y
J Immunol; 2009 Jul; 183(1):201-8. PubMed ID: 19542431
[TBL] [Abstract][Full Text] [Related]
54. Role of invariant natural killer T cells in immune regulation and as potential therapeutic targets in autoimmune disease.
Van Kaer L
Expert Rev Clin Immunol; 2006 Sep; 2(5):745-57. PubMed ID: 20477630
[TBL] [Abstract][Full Text] [Related]
55. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria.
Kinjo Y; Tupin E; Wu D; Fujio M; Garcia-Navarro R; Benhnia MR; Zajonc DM; Ben-Menachem G; Ainge GD; Painter GF; Khurana A; Hoebe K; Behar SM; Beutler B; Wilson IA; Tsuji M; Sellati TJ; Wong CH; Kronenberg M
Nat Immunol; 2006 Sep; 7(9):978-86. PubMed ID: 16921381
[TBL] [Abstract][Full Text] [Related]
56. Modification of the ceramide moiety of isoglobotrihexosylceramide on its agonist activity in stimulation of invariant natural killer T cells.
Xia C; Schümann J; Emmanuel R; Zhang Y; Chen W; Zhang W; De Libero G; Wang PG
J Med Chem; 2007 Jul; 50(15):3489-96. PubMed ID: 17608465
[TBL] [Abstract][Full Text] [Related]
57. In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells.
Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Clin Immunol; 2008 Oct; 129(1):145-54. PubMed ID: 18707922
[TBL] [Abstract][Full Text] [Related]
58. The role of iNKT cells in the immunopathology of systemic lupus erythematosus.
Gabriel L; Morley BJ; Rogers NJ
Ann N Y Acad Sci; 2009 Sep; 1173():435-41. PubMed ID: 19758183
[TBL] [Abstract][Full Text] [Related]
59. The role of iNKT cells in development of bronchial asthma: a translational approach from animal models to human.
Akbari O
Allergy; 2006 Aug; 61(8):962-8. PubMed ID: 16867051
[TBL] [Abstract][Full Text] [Related]
60. Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors.
Hayakawa Y; Berzins SP; Crowe NY; Godfrey DI; Smyth MJ
Nat Immunol; 2004 Jun; 5(6):590-6. PubMed ID: 15122252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
